Is Kalvista Pharmaceuticals Inc (KALV) overvalued? · rev $13.7M
Kalvista Pharmaceuticals Inc (KALV) is a biotechnology company listed on NASDAQ.
This page asks whether Kalvista Pharmaceuticals Inc (KALV) looks expensive on cached numbers — not a short thesis.
Latest reported KALV revenue for 2025-09-30 was $13.7M. Net income was -$158.9M. KALV currently screens at market cap $1.44B.
KALV currently screens at market cap $1.44B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next KALV 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the KALV stock page for the full model, not this heading.
Not investment advice.